1
|
Tasma Z, Wills P, Hay DL, Walker CS. Agonist bias and agonist-dependent antagonism at corticotrophin releasing factor receptors. Pharmacol Res Perspect 2021; 8:e00595. [PMID: 32529807 PMCID: PMC7290078 DOI: 10.1002/prp2.595] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Accepted: 03/26/2020] [Indexed: 01/14/2023] Open
Abstract
The corticotropin-releasing factor (CRF) receptors represent potential drug targets for the treatment of anxiety, stress, and other disorders. However, it is not known if endogenous CRF receptor agonists display biased signaling, how effective CRF receptor antagonists are at blocking different agonists and signaling pathways or how receptor activity-modifying proteins (RAMPs) effect these processes. This study aimed to address this by investigating agonist and antagonist action at CRF1 and CRF2 receptors. We used CRF1 and CRF2 receptor transfected Cos7 cells to assess the ability of CRF and urocortin (UCN) peptides to activate cAMP, inositol monophosphate (IP1 ), and extracellular signal-regulated kinase 1/2 signaling and determined the ability of antagonists to block agonist-stimulated cAMP and IP1 accumulation. The ability of RAMPs to interact with CRF receptors was also examined. At the CRF1 receptor, CRF and UCN1 activated signaling in the same manner. However, at the CRF2 receptor, UCN1 and UCN2 displayed similar signaling profiles, whereas CRF and UCN3 displayed bias away from IP1 accumulation over cAMP. The antagonist potency was dependent on the receptor, agonist, and signaling pathway. CRF1 and CRF2 receptors had no effect on RAMP1 or RAMP2 surface expression. The presence of biased agonism and agonist-dependent antagonism at the CRF receptors offers new avenues for developing drugs tailored to activate a specific signaling pathway or block a specific agonist. Our findings suggest that the already complex CRF receptor pharmacology may be underappreciated and requires further investigation.
Collapse
Affiliation(s)
- Zoe Tasma
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - Peter Wills
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - Debbie L Hay
- School of Biological Sciences, University of Auckland, Auckland, New Zealand.,Maurice Wilkins Centre and Centre for Brain Research, University of Auckland, Auckland, New Zealand
| | - Christopher S Walker
- School of Biological Sciences, University of Auckland, Auckland, New Zealand.,Maurice Wilkins Centre and Centre for Brain Research, University of Auckland, Auckland, New Zealand
| |
Collapse
|
2
|
Fontesse S, Rimez X, Maurage P. Stigmatization and dehumanization perceptions towards psychiatric patients among nurses: A path-analysis approach. Arch Psychiatr Nurs 2021; 35:153-161. [PMID: 33781393 DOI: 10.1016/j.apnu.2020.12.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 12/02/2020] [Accepted: 12/12/2020] [Indexed: 11/17/2022]
Abstract
BACKGROUND People with mental illness are stigmatized and dehumanized, which contributes to disorders' maintenance. Dehumanization is associated with abuse/neglect and should thus be evaluated among healthcare workers. We compared nurses' stigmatizing/dehumanizing perceptions of people with psychiatric versus non-psychiatric disorders. We also investigated the impact of social contact's quality/frequency and identified the determinants of dehumanization. METHODS French-speaking hospitals and nurses' associations were contacted to disseminate the survey among their employees or members. Three hundred thirty-six nurses reported their perceptions of one among three clinical populations (people with severe alcohol use disorder, schizophrenia, or cardiovascular disease). Nurses' perception of patients was evaluated through stigmatization, dehumanization, quality of contacts, structural discrimination, and evaluation of patients' life, pain, consent, and diagnostic overshadowing. Nurses' well-being was evaluated through their own perception of being dehumanized by superiors and their burnout, depression, anxiety, and stress levels. RESULTS Nurses stigmatized and dehumanized people with a psychiatric disorder more than people without a psychiatric disorder. Nurses dehumanized patients more if they felt dehumanized by their hierarchical superiors and less if they had qualitative contacts with patients. CONCLUSIONS Stigmatization and dehumanization are widespread among nurses in psychiatry, which advocates for less stigmatizing practices in healthcare settings. We propose concrete perspectives to reduce stigma/dehumanization among nurses.
Collapse
Affiliation(s)
- Sullivan Fontesse
- Louvain Experimental Psychopathology Research Group (LEP), Psychological Sciences Research Institute, UCLouvain, Place du Cardinal Mercier 10, B-1348 Louvain-la-Neuve, Belgium
| | - Ximena Rimez
- Louvain Experimental Psychopathology Research Group (LEP), Psychological Sciences Research Institute, UCLouvain, Place du Cardinal Mercier 10, B-1348 Louvain-la-Neuve, Belgium
| | - Pierre Maurage
- Louvain Experimental Psychopathology Research Group (LEP), Psychological Sciences Research Institute, UCLouvain, Place du Cardinal Mercier 10, B-1348 Louvain-la-Neuve, Belgium.
| |
Collapse
|
3
|
Harris BN. Stress hypothesis overload: 131 hypotheses exploring the role of stress in tradeoffs, transitions, and health. Gen Comp Endocrinol 2020; 288:113355. [PMID: 31830473 DOI: 10.1016/j.ygcen.2019.113355] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 12/06/2019] [Accepted: 12/06/2019] [Indexed: 12/11/2022]
Abstract
Stress is ubiquitous and thus, not surprisingly, many hypotheses and models have been created to better study the role stress plays in life. Stress spans fields and is found in the literature of biology, psychology, psychophysiology, sociology, economics, and medicine, just to name a few. Stress, and the hypothalamic-pituitaryadrenal/interrenal (HPA/I) axis and sympathetic nervous system (SNS), are involved in a multitude of behaviors and physiological processes, including life-history and ecological tradeoffs, developmental transitions, health, and survival. The goal of this review is to highlight and summarize the large number of available hypotheses and models, to aid in comparative and interdisciplinary thinking, and to increase reproducibility by a) discouraging hypothesizing after results are known (HARKing) and b) encouraging a priori hypothesis testing. For this review I collected 214 published hypotheses or models dealing broadly with stress. In the main paper, I summarized and categorized 131 of those hypotheses and models which made direct connections among stress and/or HPA/I and SNS, tradeoffs, transitions, and health. Of those 131, the majority made predictions about reproduction (n = 43), the transition from health to disease (n = 38), development (n = 23), and stress coping (n = 18). Additional hypotheses were classified as stage-spanning or models (n = 37). The additional 83 hypotheses found during searches were tangentially related, or pertained to immune function or oxidative stress, and these are listed separately. Many of the hypotheses share underlying rationale and suggest similar, if not identical, predictions, and are thus not mutually exclusive; some hypotheses spanned classification categories. Some of the hypotheses have been tested multiple times, whereas others have only been examined a few times. It is the hope that multi-disciplinary stress researchers will begin to harmonize their naming of hypotheses in the literature so as to build a clearer picture of how stress impacts various outcomes across fields. The paper concludes with some considerations and recommendations for robust testing of stress hypotheses.
Collapse
Affiliation(s)
- Breanna N Harris
- Department of Biological Sciences, Texas Tech University, Lubbock, TX, United States.
| |
Collapse
|
4
|
Butler MI, Mörkl S, Sandhu KV, Cryan JF, Dinan TG. The Gut Microbiome and Mental Health: What Should We Tell Our Patients?: Le microbiote Intestinal et la Santé Mentale : que Devrions-Nous dire à nos Patients? CANADIAN JOURNAL OF PSYCHIATRY. REVUE CANADIENNE DE PSYCHIATRIE 2019; 64:747-760. [PMID: 31530002 PMCID: PMC6882070 DOI: 10.1177/0706743719874168] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The gut microbiome as a potential therapeutic target for mental illness is a hot topic in psychiatry. Trillions of bacteria reside in the human gut and have been shown to play a crucial role in gut-brain communication through an influence on neural, immune, and endocrine pathways. Patients with various psychiatric disorders including depression, bipolar disorder, schizophrenia, and autism spectrum disorder have been shown to have significant differences in the composition of their gut microbiome. Enhancing beneficial bacteria in the gut, for example, through the use of probiotics, prebiotics, or dietary change, has the potential to improve mood and reduce anxiety in both healthy people and patient groups. Much attention is being given to this subject in the general media, and patients are becoming increasingly interested in the potential to treat mental illness with microbiome-based therapies. It is imperative that those working with people with mental illness are aware of the rationale and current evidence base for such treatment strategies. In this review, we provide an overview of the gut microbiome, what it is, and what it does in relation to gut-brain communication and psychological function. We describe the fundamental principles and basic techniques used in microbiome-gut-brain axis research in an accessible way for a clinician audience. We summarize the current evidence in relation to microbiome-based strategies for various psychiatric disorders and provide some practical advice that can be given to patients seeking to try a probiotic for mental health benefit.
Collapse
Affiliation(s)
- Mary I Butler
- Department of Psychiatry and APC Microbiome Institute, University College Cork, Ireland
| | - Sabrina Mörkl
- Department of Psychiatry and APC Microbiome Institute, University College Cork, Ireland.,Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Austria
| | - Kiran V Sandhu
- Department of Anatomy and Neuroscience and APC Microbiome Institute, University College Cork, Ireland
| | - John F Cryan
- Department of Anatomy and Neuroscience and APC Microbiome Institute, University College Cork, Ireland
| | - Timothy G Dinan
- Department of Psychiatry and APC Microbiome Institute, University College Cork, Ireland
| |
Collapse
|
5
|
Agoglia AE, Herman MA. The center of the emotional universe: Alcohol, stress, and CRF1 amygdala circuitry. Alcohol 2018; 72:61-73. [PMID: 30220589 PMCID: PMC6165695 DOI: 10.1016/j.alcohol.2018.03.009] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 03/15/2018] [Accepted: 03/27/2018] [Indexed: 12/15/2022]
Abstract
The commonalities between different phases of stress and alcohol use as well as the high comorbidity between alcohol use disorders (AUDs) and anxiety disorders suggest common underlying cellular mechanisms governing the rewarding and aversive aspects of these related conditions. As an integrative center that assigns emotional salience to a wide variety of internal and external stimuli, the amygdala complex plays a major role in how alcohol and stress influence cellular physiology to produce disordered behavior. Previous work has illustrated the broad role of the amygdala in alcohol, stress, and anxiety. However, the challenge of current and future studies is to identify the specific dysregulations that occur within distinct amygdala circuits and subpopulations and the commonalities between these alterations in each disorder, with the long-term goal of identifying potential targets for therapeutic intervention. Specific intra-amygdala circuits and cell type-specific subpopulations are emerging as critical targets for stress- and alcohol-induced plasticity, chief among them the corticotropin releasing factor (CRF) and CRF receptor 1 (CRF1) system. CRF and CRF1 have been implicated in the effects of alcohol in several amygdala nuclei, including the basolateral (BLA) and central amygdala (CeA); however, the precise circuitry involved in these effects and the role of these circuits in stress and anxiety are only beginning to be understood.
Collapse
Affiliation(s)
- Abigail E Agoglia
- Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
| | - Melissa A Herman
- Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
| |
Collapse
|
6
|
Abstract
PURPOSE OF REVIEW Stress has long been suspected to be interrelated to (abdominal) obesity. However, interindividual differences in this complex relationship exist. We suggest that the extent of glucocorticoid action partly explains these interindividual differences. We provide latest insights with respect to multiple types of stressors. RECENT FINDINGS Increased long-term cortisol levels, as measured in scalp hair, are strongly related to abdominal obesity and to specific mental disorders. However, not all obese patients have elevated cortisol levels. Possibly, the interindividual variation in glucocorticoid sensitivity, which is partly genetically determined, may lead to higher vulnerability to mental or physical stressors. Other evidence for the important role for increased glucocorticoid action is provided by recent studies investigating associations between body composition and local and systemic corticosteroids. Stress may play a major role in the development and maintenance of obesity in individuals who have an increased glucocorticoid exposure or sensitivity. These insights may lead to more effective and individualized obesity treatment strategies.
Collapse
Affiliation(s)
- Eline S van der Valk
- Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam, Room D-428, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
- Department of Internal Medicine, division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Mesut Savas
- Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam, Room D-428, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
- Department of Internal Medicine, division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Elisabeth F C van Rossum
- Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam, Room D-428, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
- Department of Internal Medicine, division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
| |
Collapse
|
7
|
Development of suitable method for large-scale urinary glucocorticoid analysis by liquid chromatography–mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1057:62-69. [DOI: 10.1016/j.jchromb.2017.04.031] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 02/08/2017] [Accepted: 04/17/2017] [Indexed: 11/19/2022]
|
8
|
Feng HP, Chien WC, Cheng WT, Chung CH, Cheng SM, Tzeng WC. Risk of anxiety and depressive disorders in patients with myocardial infarction: A nationwide population-based cohort study. Medicine (Baltimore) 2016; 95:e4464. [PMID: 27559951 PMCID: PMC5400317 DOI: 10.1097/md.0000000000004464] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Anxiety and depressive symptoms are associated with adverse cardiovascular events after an acute myocardial infarction (MI). However, most studies focusing on anxiety or depression have used rating scales or self-report methods rather than clinical diagnosis. This study aimed to investigate the association between psychiatrist-diagnosed psychiatric disorders and cardiovascular prognosis.We sampled data from the National Health Insurance Research Database; 1396 patients with MI were recruited as the study cohort and 13,960 patients without MI were recruited as the comparison cohort. Cox proportional hazard regression models were used to examine the effect of MI on the risk of anxiety and depressive disorders.During the first 2 years of follow-up, patients with MI exhibited a significantly higher risk of anxiety disorders (adjusted hazard ratio [HR] = 5.06, 95% confidence interval [CI]: 4.61-5.54) and depressive disorders (adjusted HR = 7.23, 95% CI: 4.88-10.88) than those without MI did. Greater risk for anxiety and depressive disorders was observed among women and patients aged 45 to 64 years following an acute MI. Patients with post-MI anxiety had a 9.37-fold (95% CI: 4.45-19.70) higher risk of recurrent MI than those without MI did after adjustment for age, sex, socioeconomic status, and comorbidities.This nationwide population-based cohort study provides evidence that MI increases the risk of anxiety and depressive disorders during the first 2 years post-MI, and post-MI anxiety disorders are associated with a higher risk of recurrent MI.
Collapse
Affiliation(s)
- Hsin-Pei Feng
- Institute of Medical Sciences and School of Nursing, National Defense Medical Center, Taipei City, Taiwan (ROC)
| | - Wu-Chien Chien
- Department of Medical Research, Tri-Service General Hospital and School of Public Health, National Defense Medical Center, Taipei City, Taiwan (ROC)
| | - Wei-Tung Cheng
- Kaohsiung Armed Forces General Hospital Gangshan Branch, Kaohsiung CityTaiwan (ROC)
| | - Chi-Hsiang Chung
- Taiwanese Injury Prevention and Safety Promotion Association, School of Public Health, National Defense Medical Center, Taipei City, Taiwan (ROC)
| | - Shu-Meng Cheng
- Internal Medicine, School of Medicine and Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan (ROC)
| | - Wen-Chii Tzeng
- School of Nursing, National Defense Medical Center, Taipei City, Taiwan (ROC)
- Correspondence: Wen-Chii Tzeng, School of Nursing, National Defense Medical Center, Taipei City, Taiwan (ROC) (e-mail: )
| |
Collapse
|
9
|
Fourteen-day administration of corticosterone may induce detrusor overactivity symptoms. Int Urogynecol J 2016; 27:1713-1721. [PMID: 27142032 PMCID: PMC5065892 DOI: 10.1007/s00192-016-3027-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2016] [Accepted: 04/11/2016] [Indexed: 12/19/2022]
Abstract
Introduction and hypothesis Epidemiological studies demonstrated that patients suffering from overactive bladder often present with different mental problems, amongst which depression is the most frequently observed. The main goal of our study was to check if the repeated administration of corticosterone (CORT) is able to evoke the depressive-like behaviour and detrusor overactivity (DO) symptoms in rats. Moreover, we investigated whether the acute administration of common antidepressants (imipramine, 30 mg/kg, and fluoxetine, 15 mg/kg), antimuscarinic (oxybutynin chloride, 0.5 mg/kg) or CRF1 (SN 003, 1 mg/kg) antagonists has an impact on the cystometric parameters, behaviour in the Porsolt test, and overall locomotor activity of animals exposed to CORT. Methods The experiments were carried out on female Wistar rats. All applied surgical and histopathology procedures, cystometric investigations, locomotor activity and forced swim measurements have been fully described in the published literature. Results Fourteen-day administration of CORT may induce both depressive and DO symptoms in rats, which are reversed by the inhibition of CRF1 receptors. Conclusions It seems that the CRF1 receptor could be an interesting target for overactive bladder pharmacotherapy, particularly in patients with co-existing depression.
Collapse
|
10
|
Dalvie S, Fabbri C, Ramesar R, Serretti A, Stein DJ. Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders. Metab Brain Dis 2016; 31:183-9. [PMID: 26563126 DOI: 10.1007/s11011-015-9762-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 11/06/2015] [Indexed: 01/13/2023]
Abstract
Glutamatergic neurotransmission has been shown to be dysregulated in bipolar disorder (BD), alcohol use disorder (AUD) and substance use disorder (SUD). Similarly, disruption in the hypothalamic-pituitary-adrenal (HPA)-axis has also been observed in these conditions. BD is often comorbid with AUD and SUD. The effects of the glutamatergic and HPA systems have not been extensively examined in individuals with BD-AUD and BD-SUD comorbidity. The aim of this investigation was to determine whether variants in the glutamatergic pathway and HPA-axis are associated with BD-AUD and BD-SUD comorbidity. The research cohort consisted of 498 individuals with BD type I from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). A subset of the cohort had comorbid current AUD and current SUD. A total of 1935 SNPs from both the glutamatergic and HPA pathways were selected from the STEP-BD genome-wide dataset. To identify population stratification, IBS clustering was performed using the program Plink 1.07. Single SNP association and gene-based association testing were conducted using logistic regression. A pathway analysis of glutamatergic and HPA genes was performed, after imputation using IMPUTE2. No single SNP was associated with BD-AUD or BD-SUD comorbidity after correction for multiple testing. However, from the gene-based analysis, the gene PRKCI was significantly associated with BD-AUD. The pathway analysis provided overall negative findings, although several genes including GRIN2B showed high percentage of associated SNPs for BD-AUD. Even though the glutamatergic and HPA pathways may not be involved in BD-AUD and BD-SUD comorbidity, PRKCI deserves further investigation in BD-AUD.
Collapse
Affiliation(s)
- Shareefa Dalvie
- MRC/UCT Human Genetics Research Unit, Division of Human Genetics, University of Cape Town, Observatory, Cape Town, South Africa.
| | - Chiara Fabbri
- Institute of Psychiatry, University of Bologna, Viale Carlo Pepoli 5, Bologna, Italy
| | - Raj Ramesar
- MRC/UCT Human Genetics Research Unit, Division of Human Genetics, University of Cape Town, Observatory, Cape Town, South Africa
| | - Alessandro Serretti
- Institute of Psychiatry, University of Bologna, Viale Carlo Pepoli 5, Bologna, Italy
| | - Dan J Stein
- Department of Psychiatry and Mental Health, University of Cape Town, Observatory, Cape Town, South Africa
| |
Collapse
|
11
|
Zhang W, Zhao R, Li X, Cui X, Zhao Z, Mao Y, Wu F, Tang Q. Effect of Yi-nao-jie-yu decoction on γ-aminobutyric acid type A receptor in the hippocampus and serum inflammatory factors in a rat model of poststroke anxiety. Neuropsychiatr Dis Treat 2016; 12:2827-2837. [PMID: 27843317 PMCID: PMC5098770 DOI: 10.2147/ndt.s115116] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND The Yi-nao-jie-yu decoction (YNJYD) is a herbal preparation widely used in the clinics of traditional Chinese medicine and has been recently used as an important new therapeutic agent in poststroke anxiety (PSA). The neuroendocrine-immune system plays an important role in PSA mechanisms, although the modulating effects of YNJYD remain unknown. This study investigated the potential effects of YNJYD on the neuroendocrine-immune system in a rat model of PSA. MATERIALS AND METHODS The PSA model was induced by injecting collagenase (type VII) into the right globus pallidus, accompanied by empty water bottle stimulation for 2 weeks. The sham group and the PSA model group were gavaged with saline, while the treatment groups received buspirone (BuSpar) or YNJYD. Behavior was evaluated with the open field test and elevated plus maze once a week. Pathological changes were observed by hematoxylin and eosin staining. Serum levels of tumor necrosis factor, interleukin (IL)-6, adrenocorticotropic hormone, thyroid stimulating hormone, free triiodothyronine, free thyroxine, IL-1α, and cortisol were detected by radioimmunoassay. Expression of the γ-aminobutyric acid type A receptor (GABAAR) α2 subunit was examined by Western blot and real-time polymerase chain reaction. RESULTS YNJYD-treated rats exhibited significantly better recovery than BuSpar-treated rats at 21 days and 28 days in the open field test and elevated plus maze. Hematoxylin and eosin staining revealed neural repair in the hippocampus in the treatment groups. Serum levels of IL-1α in the YNJYD group were significantly less than those in the model group and the BuSpar group. GABAAR protein and mRNA expressions were higher in the PSA model group than in the sham group, and YNJYD reversed these effects. CONCLUSION YNJYD alleviated the symptoms of PSA mainly by decreasing IL-1α levels and downregulating GABAAR expression in the hippocampus to maintain a neuroendocrine-mmune system balance.
Collapse
Affiliation(s)
- Wen Zhang
- Department of Encephalopathy, The Third Affiliated Hospital
| | - Ruizhen Zhao
- Department of Encephalopathy, The Third Affiliated Hospital
| | - Xiaoli Li
- Department of Encephalopathy, The Third Affiliated Hospital
| | - Xia Cui
- Department of Encephalopathy, The Third Affiliated Hospital
| | - Zijun Zhao
- Department of Encephalopathy, The Third Affiliated Hospital
| | | | - Fengzhi Wu
- Center of Journals, Beijing University of Chinese Medicine, Chaoyang District, Beijing, People's Republic of China
| | - Qisheng Tang
- Department of Encephalopathy, The Third Affiliated Hospital
| |
Collapse
|
12
|
Ho JTK, Chan GCF, Li JCB. Systemic effects of gut microbiota and its relationship with disease and modulation. BMC Immunol 2015; 16:21. [PMID: 25896342 PMCID: PMC4404277 DOI: 10.1186/s12865-015-0083-2] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 03/11/2015] [Indexed: 02/08/2023] Open
Abstract
The gut microbiota makes up the majority of the human bacterial population, and although the gut microbiota resides in the intestines, it is able to exert systemic effects. Therefore, many diseases and conditions could be impacted by the gut microbiota when its composition is imbalanced, otherwise known as dysbiosis. However, apart from understanding the illnesses, we must also try to understand the intestinal flora itself to move forward and develop potential treatments.
Collapse
Affiliation(s)
- Jolie T K Ho
- Department of Paediatrics and Adolescent Medicine LKS Faculty of Medicine, The University of Hong Kong, Room L2-01, Laboratory Block, 21 Sassoon Road, Hong Kong, China.
| | - Godfrey C F Chan
- Department of Paediatrics and Adolescent Medicine LKS Faculty of Medicine, The University of Hong Kong, Room L2-01, Laboratory Block, 21 Sassoon Road, Hong Kong, China.
| | - James C B Li
- Department of Paediatrics and Adolescent Medicine LKS Faculty of Medicine, The University of Hong Kong, Room L2-01, Laboratory Block, 21 Sassoon Road, Hong Kong, China.
| |
Collapse
|
13
|
Savic D, Knezevic G, Damjanovic S, Antic J, Matic G. GR gene BclI polymorphysm changes the path, but not the level, of dexamethasone-induced cortisol suppression. J Affect Disord 2014; 168:1-4. [PMID: 25033471 DOI: 10.1016/j.jad.2014.06.046] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2013] [Revised: 06/24/2014] [Accepted: 06/26/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND The hypothalamo-pituitary-adrenocortical (HPA) axis self-regulation is achieved via cortisol binding to mineralocorticoid (MR) and glucocorticoid receptors (GR). It is often disturbed in mental disorders, particularly in those where traumatic stress has been implicated, such as posttraumatic stress disorder and depression. Although dexamethasone suppression test (DST) is often used as diagnostic aid, the findings still vary. In search of the factors influencing the DST outcome, we examined the glucocorticoid receptor (GR) gene BclI polymorphism. METHODS A total of 229 male subjects were classified into three BclI groups: two groups with homozygous carriers (of the G allele, N=108, and of the C allele, N=26), and one with heterozygous carriers (N=95). Multiple hierarchical linear regression analysis was done, where the dependent variable was the dexamethasone-induced cortisol suppression, and predictors included receptor variables. The interactions of the count of 'G׳s with the predictors were introduced to single out the effects of the G allele. RESULTS The means of all studied variables, including suppression, are statistically the same in the three groups. However, the mechanism of suppression involves MRs only in the G allele carriers. LIMITATIONS The subjects were selected by criteria suited for the aim of the large project whose part is this study, hence the relatively small number of CC carriers. Also, we did not assess MR functional properties that would probably sharpen the results. CONCLUSION Our finding that MRs participate in cortisol suppression in the G allele carriers suggests that research aimed at refining HPA axis-based therapy might require its adjustment for such patients.
Collapse
Affiliation(s)
- Danka Savic
- Vinca Institute, Laboratory for Theoretical and Condensed Matter Physics 020/2, University of Belgrade, PO Box 522, 11001 Belgrade, Serbia.
| | - Goran Knezevic
- University of Belgrade, Faculty of Philosophy, School of Psychology, Belgrade, Serbia
| | - Svetozar Damjanovic
- Institute of Endocrinology, Diabetes and Metabolic Disease, University of Belgrade, Belgrade, Serbia
| | - Jadranka Antic
- Institute of Endocrinology, Diabetes and Metabolic Disease, University of Belgrade, Belgrade, Serbia
| | - Gordana Matic
- Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Belgrade, Serbia
| |
Collapse
|
14
|
Rivier JE, Rivier CL. Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance. Front Neuroendocrinol 2014; 35:161-70. [PMID: 24269930 PMCID: PMC3965584 DOI: 10.1016/j.yfrne.2013.10.006] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2013] [Revised: 10/18/2013] [Accepted: 10/20/2013] [Indexed: 12/19/2022]
Abstract
Elusive for more than half a century, corticotropin-releasing factor (CRF) was finally isolated and characterized in 1981 from ovine hypothalami and shortly thereafter, from rat brains. Thirty years later, much has been learned about the function and localization of CRF and related family members (Urocortins 1, 2 and 3) and their 2 receptors, CRF receptor type 1 (CRFR1) and CRF receptor type 2 (CRFR2). Here, we report the stepwise development of peptide CRF agonists and antagonists, which led to the CRFR1 agonist Stressin1; the long-acting antagonists Astressin2-B which is specific for CRFR2; and Astressin B, which binds to both CRFR1 and CRFR2.This analog has potential for the treatment of CRF-dependent diseases in the periphery, such as irritable bowel syndrome.
Collapse
Affiliation(s)
- Jean E Rivier
- The Salk Institute, The Clayton Foundation Laboratories for Peptide Biology, La Jolla, CA 92037, USA.
| | - Catherine L Rivier
- The Salk Institute, The Clayton Foundation Laboratories for Peptide Biology, La Jolla, CA 92037, USA
| |
Collapse
|
15
|
Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system. J Neurosci 2013; 33:1088-98. [PMID: 23325246 DOI: 10.1523/jneurosci.2331-12.2013] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
It has been suggested that severe adverse life events during pregnancy increase the risk of schizophrenia in the offspring. The serotonin 5-HT(2A) and the metabotropic glutamate 2 (mGlu2) receptors both have been the target of considerable attention regarding schizophrenia and antipsychotic drug development. We tested the effects of maternal variable stress during pregnancy on expression and behavioral function of these two receptors in mice. Prenatal stress increased 5-HT(2A) and decreased mGlu2 expression in frontal cortex, a brain region involved in perception, cognition, and mood. This pattern of expression of 5-HT(2A) and mGlu2 receptors was consistent with behavioral alterations, including increased head-twitch response to the hallucinogenic 5-HT(2A) agonist DOI [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane] and decreased mGlu2-dependent antipsychotic-like effect of the mGlu2/3 agonist LY379268 (1R,4R,5S,6R-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate) in adult, but not prepubertal, mice born to stressed mothers during pregnancy. Cross-fostering studies determined that these alterations were not attributable to effects of prenatal stress on maternal care. Additionally, a similar pattern of biochemical and behavioral changes were observed in mice born to mothers injected with polyinosinic:polycytidylic acid [poly(I:C)] during pregnancy as a model of prenatal immune activation. These data strengthen pathophysiological hypotheses that propose an early neurodevelopmental origin for schizophrenia and other psychiatric disorders.
Collapse
|
16
|
Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS One 2011; 6:e19298. [PMID: 21541294 PMCID: PMC3082569 DOI: 10.1371/journal.pone.0019298] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2010] [Accepted: 04/01/2011] [Indexed: 11/20/2022] Open
Abstract
Background Cardiovascular disease is the leading cause of mortality among patients with serious mental illness (SMI) and the prevalence of metabolic syndrome—a constellation of cardiovascular risk factors—is significantly higher in these patients than in the general population. Metabolic monitoring among patients using second generation antipsychotics (SGAs)—a risk factor for metabolic syndrome—has been shown to be inadequate despite the release of several guidelines. However, patients with SMI have several factors independent of medication use that predispose them to a higher prevalence of metabolic syndrome. Our study therefore examines monitoring and prevalence of metabolic syndrome in patients with SMI, including those not using SGAs. Methods and Findings We retrospectively identified all patients treated at a Veterans Affairs Medical Center with diagnoses of schizophrenia, schizoaffective disorder or bipolar disorder during 2005–2006 and obtained demographic and clinical data. Incomplete monitoring of metabolic syndrome was defined as being unable to determine the status of at least one of the syndrome components. Of the 1,401 patients included (bipolar disorder: 822; schizophrenia: 222; and schizoaffective disorder: 357), 21.4% were incompletely monitored. Only 54.8% of patients who were not prescribed SGAs and did not have previous diagnoses of hypertension or hypercholesterolemia were monitored for all metabolic syndrome components compared to 92.4% of patients who had all three of these characteristics. Among patients monitored for metabolic syndrome completely, age-adjusted prevalence of the syndrome was 48.4%, with no significant difference between the three psychiatric groups. Conclusions Only one half of patients with SMI not using SGAs or previously diagnosed with hypertension and hypercholesterolemia were completely monitored for metabolic syndrome components compared to greater than 90% of those with these characteristics. With the high prevalence of metabolic syndrome seen in this population, there appears to be a need to intensify efforts to reduce this monitoring gap.
Collapse
|
17
|
Karaiskos D, Mavragani CP, Sinno MH, Déchelotte P, Zintzaras E, Skopouli FN, Fetissov SO, Moutsopoulos HM. Psychopathological and personality features in primary Sjogren's syndrome--associations with autoantibodies to neuropeptides. Rheumatology (Oxford) 2010; 49:1762-9. [PMID: 20525741 DOI: 10.1093/rheumatology/keq158] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES To determine the spectrum of personality and psychopathology features of patients with primary SS (pSS) and explore whether they are linked to disease characteristics as well as the presence of autoantibodies (autoAbs) against neuropeptides. METHODS Personality and psychopathological variables were determined in 103 pSS patients and 110 healthy controls (HCs). AutoAbs against hypothalamic and pituitary neuropeptides were measured by ELISA in 25 pSS patients and 25 HCs. Data analysis was performed by univariate and multivariate logistic regression models and by comparison with regression models. RESULTS A higher number of pSS patients reported distinct personality traits (neuroticism, psychoticism and obsessiveness) and psychological distress compared with HCs. After adjustment for personality characteristics and demographics, only hypochondriasis was the main psychopathology feature associated with pSS, suggesting that psychopathological manifestations in the setting of pSS are primarily dependent on premorbid personality characteristics. Although no differences were detected between serum levels of neuropeptide autoAbs in pSS cases and controls, levels of autoAbs against alpha-melanocyte-stimulating hormone (alpha-MSH) correlated with anxiety scores in both groups examined but with higher intercept in pSS subjects. Significant correlations between anxiety score and autoAbs directed against oxytocin and vasopressin were also detected in the pSS patients. CONCLUSIONS pSS patients exhibit a distinct pattern of personality traits and high levels of psychological distress compared with HCs, which seems to be determined by premorbid personality characteristics. Correlations between anxiety and alpha-MSH autoAbs suggest their potential involvement in anxiety development in both pSS and HCs.
Collapse
Affiliation(s)
- Dimitrios Karaiskos
- Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 2010; 27:417-25. [PMID: 20455246 DOI: 10.1002/da.20695] [Citation(s) in RCA: 125] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND Antagonism of corticotropin-releasing factor (CRF) receptors has been hypothesized as a potential target for the development of novel anxiolytics. This study was designed to determine the safety and efficacy of pexacerfont, a selective CRF-1 receptor antagonist, in the treatment of generalized anxiety disorder (GAD). METHOD This was a multicenter, randomized, double-blind, placebo-controlled and active comparator trial. Two hundred and sixty patients were randomly assigned to pexacerfont 100 mg/day (after a 1 week loading dose of 300 mg/day), placebo or escitalopram 20 mg/day in a 2:2:1 ratio. The primary outcome was the mean change from baseline to end point (week 8) in the Hamilton Anxiety Scale total score. RESULTS Pexacerfont 100 mg/day did not separate from placebo on the primary outcome measure. The half-powered active comparator arm, escitalopram 20 mg/day, demonstrated efficacy with significant separation from placebo at weeks 1, 2, 3, 6, and 8 (P<.02). Response rates for pexacerfont, placebo, and escitalopram were 42, 42, and 53%, respectively. Genetic and psychometric rating scale data was obtained in 175 randomized subjects. There was a significant association between a single nucleotide polymorphism (SNP) of the gene encoding plexin A2 (PLXNA2-2016) with the HAM-A psychic subscale score for the entire cohort at baseline (FDR-adjusted P=.015). CONCLUSIONS Pexacerfont did not demonstrate efficacy compared to placebo for the treatment of GAD. Whether these findings are generalizable to this class of agents remains to be determined. Our preliminary genetic finding of an association between a SNP for the gene encoding plexin A2 and an anxiety phenotype in this study merits further exploration. The trial was registered at clinicaltrials.gov (NCT00481325) before enrollment.
Collapse
Affiliation(s)
- Vladimir Coric
- Bristol-Myers Squibb Company, Neuroscience Global Clinical Research, Wallingford, Connecticut 06492, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Zimmerman DJ, Choi-Kain LW. The hypothalamic-pituitary-adrenal axis in borderline personality disorder: a review. Harv Rev Psychiatry 2009; 17:167-83. [PMID: 19499417 DOI: 10.1080/10673220902996734] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
BACKGROUND borderline personality disorder (BPD) is a psychiatric diagnosis characterized by high exposure, reactivity, and vulnerability to stress. Given these abnormalities in stress reactivity in BPD, there is a question of whether the hypothalamic-pituitary-adrenal (HPA) axis functions normally in BPD, since the activation of the HPA axis normally occurs to coordinate both behavioral and physiologic responses to stress. Several studies have investigated the functioning of the HPA axis in BPD and have shown varied results. This review seeks to summarize and interpret the findings of this growing literature. METHODS Pubmed search for English language articles on borderline personality disorder and hypothalamic-pituitary-adrenal axis. RESULTS findings are mixed but suggest that important variables relevant to between-group differences include comorbid depression, comorbid posttraumatic stress disorder, dissociative symptoms, and history of childhood abuse. DISCUSSION comorbid diagnoses and clinical features such as trauma history and symptom severity may have variable, interacting influences on the psychoneuroendocrine profile in BPD. Also explored here are the implications of these findings for developing possible models of HPA-axis dysfunction in BPD, for identifying potential targets for treatment, and for improving the methodology of future studies.
Collapse
Affiliation(s)
- Daniel J Zimmerman
- Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
| | | |
Collapse
|
20
|
Zill P, Büttner A, Eisenmenger W, Müller J, Möller HJ, Bondy B. Predominant expression of tryptophan hydroxylase 1 mRNA in the pituitary: a postmortem study in human brain. Neuroscience 2009; 159:1274-82. [PMID: 19233335 DOI: 10.1016/j.neuroscience.2009.01.006] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2008] [Revised: 12/18/2008] [Accepted: 01/04/2009] [Indexed: 10/21/2022]
Abstract
Although the predominant role of tryptophan hydroxylase 2 (TPH2) in the CNS and its influence on the vulnerability to psychiatric disorders have clearly been demonstrated in several studies, the role of TPH1 on neuronal mechanisms, respectively on behavioral traits is still poorly understood. In a previous study of tryptophan hydroxylase 1 (TPH1) and TPH2 mRNA expression in different human brain regions we observed significantly higher TPH1 than TPH2 mRNA concentrations in the pituitary (unpublished observations). Considering the importance of the pituitary in the functional circuits between brain and body, we investigated the TPH1 and TPH2 mRNA expression in more detail, using human postmortem samples of the posterior and anterior pituitary compared to cortex, hippocampus and raphe nuclei. Specimens were available from different psychiatric patients (drug abusers, n=12; suicide victims, n=11; schizophrenics, n=9) and controls (n=15). Additionally we performed immunohistochemical analysis applying monospecific antibodies for both TPH isoforms to verify that the mRNA is of cellular and not just vascular or other origin. Highest TPH2 mRNA levels were observed in the raphe nuclei in patients and controls. By contrast, in the anterior and posterior pituitary TPH1 was found to be the predominantly expressed isoform in all subgroups. TPH1 and TPH2 mRNA expression in the further brain regions was only marginal and nearly identical except in the hypothalamus where higher TPH1 than TPH2 mRNA levels could be measured. Interindividual differences between the subgroups were not detectable. The results of the present study extended our previous findings by the additional immunohistochemical determination of the neuronal TPH1 and TPH2 protein expression in the anterior pituitary and provide evidence against a strictly separated duality of the serotonergic system. It seems that TPH1 might also have an impact on neuronal mechanisms via hypothalamic-pituitary-adrenal axis regulation by its predominant localization in the pituitary. These observations may open up new research strategies not only for several psychiatric disorders, but also for the relationship between psychiatric and somatic diseases.
Collapse
Affiliation(s)
- P Zill
- Department of Psychiatry, Ludwig-Maximilians-University Munich, Munich, Germany.
| | | | | | | | | | | |
Collapse
|